Interpretation of Mildly Increased Pulmonary Markings Along Bronchovascular Bundles

Primary Differential Diagnosis

The American Thoracic Society and European Respiratory Society state that mildly increased pulmonary markings along bronchovascular bundles on chest x-ray most commonly indicate bronchial wall thickening from chronic airway inflammation, typically seen in asthma, COPD, or chronic bronchitis, and recommend obtaining spirometry to confirm airflow limitation and exclude alternative diagnoses such as heart failure, interstitial lung disease, or pulmonary vascular disease 1, 2
Chronic airway disease (COPD/asthma) is the most common cause of increased bronchovascular markings in patients with respiratory symptoms and smoking history, according to the American Journal of Respiratory and Critical Care Medicine and European Respiratory Journal 1, 2
Early pulmonary vascular congestion, characterized by increased bronchovascular markings, can be a presentation of heart failure before frank pulmonary edema develops, as noted by Praxis Medical Insights 3

The American Thoracic Society/European Respiratory Society guidelines recommend that spirometry is mandatory to confirm or exclude airflow limitation, as chest x-ray alone cannot diagnose COPD or asthma, and state that chest radiography is frequently normal in early COPD 1, 2, 4
Smoking exposure, including pack-years and current status, should be obtained in the clinical history, as recommended by the American Journal of Respiratory and Critical Care Medicine and European Respiratory Journal 1, 2
Occupational/environmental exposures, such as dust, chemicals, and biomass fuels, should be assessed in the clinical history, according to the American Journal of Respiratory and Critical Care Medicine and European Respiratory Journal 1, 2
Symptom pattern, including chronic cough, sputum production, progressive dyspnea, or episodic wheezing, should be evaluated in the clinical history, as recommended by the American Journal of Respiratory and Critical Care Medicine and European Respiratory Journal 1, 2

The American College of Radiology recommends CT chest without IV contrast only in specific circumstances, such as suspected structural complications, lung cancer screening, interstitial lung disease, or pulmonary hypertension evaluation, as noted by the American Journal of Respiratory and Critical Care Medicine, European Respiratory Journal, and European Respiratory Review 1, 2, 7
CT with contrast adds no diagnostic value for parenchymal lung disease assessment, according to Praxis Medical Insights 5

The European Respiratory Society mandates spirometry confirmation before initiating COPD pharmacotherapy, and starting bronchodilators or inhaled corticosteroids based solely on radiographic findings is inappropriate, as noted by Praxis Medical Insights 5
The American Thoracic Society/European Respiratory Society emphasizes that chest radiography's primary role is excluding other diseases causing similar symptoms, such as heart failure, lung cancer, and pneumonia, as recommended by the American Journal of Respiratory and Critical Care Medicine, European Respiratory Journal, and Clinical Microbiology and Infection 1, 2, 4, 8

If spirometry shows reversible obstruction (asthma), the American Thoracic Society/European Respiratory Society recommends initiating inhaled corticosteroid plus as-needed short-acting beta-agonist, although this is not directly cited in the provided references
If spirometry shows fixed obstruction (COPD), the American Journal of Respiratory and Critical Care Medicine and European Respiratory Journal recommend starting long-acting bronchodilator therapy, and considering inhaled corticosteroids if frequent exacerbations (≥2 per year), as noted by Clinical Microbiology and Infection 1, 2, 8
Smoking cessation is mandatory for COPD patients, as recommended by the American Journal of Respiratory and Critical Care Medicine and European Respiratory Journal 1, 2

The American Thoracic Society/European Respiratory Society guidelines explicitly state that chest radiography is not performed during routine follow-up of stable COPD or asthma patients, as noted by the American Journal of Respiratory and Critical Care Medicine and European Respiratory Journal 1, 2
Repeat imaging is indicated only for acute exacerbations with clinical deterioration, suspected complications, or lung cancer surveillance, as recommended by Praxis Medical Insights and the American Journal of Respiratory and Critical Care Medicine 1, 3, 4, 5